

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

JAMES KEESE

2. Address:

400 NORTH CAPITOL STREET NW SUITE 585, WASHINGTON, DC 20001

3. Principal place of business (if different from line 2):

Country: City: State/Zip(or Country):

4. Contact Name: AMY MCIFFF

Telephone: 202-624-1498

E-mail (optional): amcifff@cagdc.com

Senate ID #: 74556-12

House ID #: 36042000

7. Client Name: ☐ Self

TEVA PHARMACEUTICALS USA

TYPE OF REPORT

8. Year 2005 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 80,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

None

17. House(s) of Congress and Federal agencies contacted:
U.S. House of Representatives.

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above.
Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above.

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 2795, The Patent Reform Act of 2005; all provisions. Patent reform matters.

17. House(s) of Congress and Federal agencies contacted:

U.S. House of Representatives; U.S. Senate.

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above.

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

S. 1932, Deficit Reduction Omnibus Reconciliation Act of 2005; all provisions. H.R. 4241, Deficit Reduction Act of 2005; all provisions.

17. House(s) of Congress and Federal agencies contacted:

U.S. House of Representatives; U.S. Senate. Department of Health and Human Services; The White House.

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above.

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

S. 976, Project Bioshield II Act of 2005; all provisions. S. 3, Protecting America in the War on Terror Act of 2005; all provisions. S. 1873, Biodefense and Pandemic Vaccine and Drug Development Act of 2005; all provisions. H.R. 2862, Science, State, Justice, Commerce, and Related Agencies Appropriations Act of 2006; Wolf Amendment regarding DEA authority on importation of controlled substances.

17. House(s) of Congress and Federal agencies contacted:
U.S. House of Representatives; U.S. Senate.

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: JAMES KEESE Client Name: TEVA PHARMACEUTICALS USA

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

Central American Free Trade Agreement.

17. House(s) of Congress and Federal agencies contacted:

U. S. House of Representatives; U.S. Senate.

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above.

Signature: ON FILE Date: Feb 14, 2006

Printed Name and Title: James Keese, III, Principal -